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ABSTRACT
The need to develop an insulin delivery system
that can closely mimic physiologically induced
changes in prandial insulin release has been a
major research target since the discovery of
insulin. The challenges facing existing insulin
delivery systems, related to relatively slow
pharmacokinetics and pharmacodynamics,
have been further highlighted by rapid
advances in diabetes technology and progress
in artificial pancreas research. Despite the
growing interest in alternative routes of insulin
administration, the subcutaneous route
remains—at least for now—the preferred route
for insulin administration. In this article, we
review efforts aimed at developing
subcutaneously injected ultrafast-acting insulin
and measures aimed at enhancing insulin
absorption, focusing on local warming devices.
Keywords: Insulin absorption; Insulin therapy;
InsuPad; InsuPatch; Postprandial glycaemia
INTRODUCTION
In people with normal glucose tolerance, the
endogenous insulin profile combines constant
pulsatile basal insulin production with prandial
insulin secretion. The main role of basal insulin
is to limit hepatic glucose production while
maintaining adequate glucose for cerebral
function. Following a mixed meal, the rise in
blood glucose is rapidly sensed by beta cells in
the pancreas, resulting in insulin release, over
two phases, into the portal circulation and a
rapid rise in circulating insulin levels. This
results in suppression of hepatic glucose
production followed by stimulation of glucose
utilisation in the main insulin-dependent
tissues (e.g. skeletal muscle and adipose
tissue), preventing a postprandial rise in blood
glucose levels [1].
In healthy nonobese adults, insulin is
secreted at a basal rate of 0.5–1 U per hour,
resulting in plasma concentrations of 5–15 mU/
L in fasting conditions [1]. Following a mixed
meal, plasma insulin levels reach half of the
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maximal concentration in approximately
16–18 min and peak at 60–80 mU/L within
45 min before returning to baseline 2–4 h later
[2].
Since the discovery of insulin in 1922, there
have been continuous advances in the field of
insulin therapy, with the aim being to develop
insulin delivery systems that can mimic
physiological insulin secretion. However,
several factors affect the pharmacokinetics (PK)
and pharmacodynamics (PD) of exogenously
administered insulin. These include insulin
formulation, dose and concentration, as well
as mode of administration, injection site,
injection depth, infusion site age, exercise,
local massage, temperature and individual
variation in obesity, age, and smoking [2–7].
The subcutaneous tissue structure limits the
spread of injectable insulin and its absorption
into the systemic circulation. This impacts
insulin PK and PD with delayed onset, a
delayed peak and a longer duration of insulin
action, making postprandial glucose
optimisation challenging, with early
postprandial glycaemic (PPG) excursions and a
risk of late postprandial hypoglycaemia,
negatively affecting the overall glycaemic
control as assessed by HbA1c [8]. This increase
in glycaemic variability may also contribute to
diabetes-related complications, independently
of HbA1c [9, 10].
The introduction in the 1990s of
rapid-acting insulin analogues (RAIAs), with
insulin absorption and a metabolic effect that
are accelerated compared to regular human
insulin (RHI), has resulted in improved
diabetes management. The faster onset and
peak of action allow the time interval between
insulin injection and meals to be shortened and
postprandial glycaemic excursions to be
reduced [11]. The shorter duration of action
also reduces the risk of hypoglycaemia [12].
Evidence from meta-analyses also shows the
beneficial effect of RAIAs compared to RHI in
reducing HbA1c in both type 1 and type 2
diabetes [13, 14]. Moreover, the earlier rise in
insulin levels obtained with RAIAs, simulating
the first-phase insulin response, may have a
more pronounced impact on the suppression of
hepatic glucose production with a subsequent
significant reduction in PPG [15]. Current RAIAs
(lispro, aspart and glulisine) have similar PK/PD
profiles, with the onset of insulin exposure
occurring in 5–15 min, a peak at 45–60 min and
an overall duration of about 3–4 h [11]. Despite
the benefits provided by RAIAs, these
formulations remain slower than physiological
insulin secretion since their glucose-lowering
effect can take 2–3 h to peak and can last for
5–6 h [16]. Several studies have demonstrated
that an injection to meal time interval of
15–20 min was required to shift the action
profile of RAIAs to achieve a better overlap
with the postprandial glucose profile and
optimally reduce PPG excursions without
increasing the risk of hypoglycaemia [17–19].
However, inconvenience and the increased risk
of periprandial hypoglycaemia are likely to be a
barrier to an early injection to meal interval in
reality. Furthermore, the relatively slow PK/PD
of RAIAs represent a challenge to artificial
pancreas algorithms. The delay between the
start of a meal and rise of interstitial fluid
glucose, which triggers automatic insulin
delivery, is exacerbated by the slow PK/PD of
existing insulin formulations, resulting in large
PPG excursions. Therefore, the development of
novel formulations and methods that modify
insulin PK/PD to mimic the endogenous insulin
profile remains a major research target.
Euglycaemic glucose-clamp studies are
frequently used to assess PK (insulin exposure)
and PD (insulin action) of insulins. The serum
insulin concentration reflects insulin exposure,
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while glucose infusion rate (GIR) reflects insulin
action. The onset, time to peak and offset are
represented by early t50%, tmax and late t50%,
respectively. Other important parameters
include maximum insulin concentration
(Cmax), maximum GIR (GIRmax) and area
under the curve (AUC). The AUC for insulin
represents the overall bioavailability of injected
insulin, while the AUC for GIR represents the
overall glucose-lowering effect [1].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
INNOVATIONS AIMING
TO ENHANCE ABSORPTION
OF SUBCUTANEOUSLY INJECTED
INSULIN
Several methods that are aimed at enhancing
prandial insulin delivery to the systemic
circulation have been studied. These include
studies to investigate alternative routes of
insulin administration to the traditional
subcutaneous route, such as inhaled
Technosphere insulin (Afrezza), buccal spray
insulin (Oral-lyn), intraperitoneal and
intradermal delivery [2, 20–23]. Innovations
aimed at enhancing the absorption of
subcutaneous insulin include the development
of novel formulations that contain excipients
such as citrate and disodium
ethylenediaminetetraacetic acid in VIAject [24]
or nicotinamide and arginine in faster-acting
insulin aspart (FIAsp) [25].
BioChaperone Lispro (Adocia, Lyon, France)
is a novel insulin formulation that comprises
the proprietary BioChaperone platform. This is
a library of polysaccharide derivatives that are
designed to form a reversible molecular
complex with therapeutic proteins, e.g.
insulin. This protects insulin from enzymatic
degradation and enhances its stability and
solubility, with subsequent enhancement of
absorption and bioavailability [26, 27].
A recent study has demonstrated the effect of
the addition of recombinant human
hyaluronidase (rHuPH20) on enhancing PK/PD
profiles of co-injected RAIAs [28]. The
FDA-approved Hylenex recombinant human
hyaluronidase (Halozyme Therapeutics, San
Diego, CA, USA) transiently and reversibly
degrades hyaluronan to enhance the diffusion
and absorption of co-injected insulin.
The use of jet spray injectors has also been
investigated as a method to enhance insulin
absorption [29, 30]. Initially designed for people
with needle phobia, jet spray injectors work by
sending a fine spray of insulin through the skin
into subcutaneous tissue using a high-velocity
jet, allowing insulin delivery without the need
to use a needle to puncture the skin. They
enhance insulin absorption by mechanically
dispersing insulin into a large area of the
subcutaneous tissue. The use of jet injectors is
limited by the need for training, their cost and
the potential discomfort caused by the
high-velocity jet.
This article reviews evidence relating to the
use of local warming devices (InsuPatch and
InsuPad) as tools to increase the absorption of
subcutaneously injected insulin and enhance its
PK/PD profile. A literature review was performed
using PubMed, the Cochrane Library database
and Web of Science to identify relevant studies.
Search terms used were ‘‘insulin absorption’’,
‘‘insulin pharmacokinetics’’ and ‘‘insulin
pharmacodynamics’’ followed by a keyword
search for ‘‘local warming’’ and ‘‘local heating’’.
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Other search terms used were ‘‘InsuPad’’ and
‘‘InsuPatch’’.
LOCAL WARMING DEVICES
Principle and Mechanism of Action
The effect of ambient temperature on insulin PK
has been recognised. Exposure to a sauna at 85 C
for 50 min resulted in an increase in insulin
absorption of 110% and a reduction in
postprandial glycaemic excursions compared to
a control environment of 22 C [31]. This effect
on insulin PK is produced through an increase in
local blood flow and was demonstrated in
another study in which a rise in ambient
temperature from 20 to 35 C resulted in a 25%
increment in skin temperature, a two- to
threefold increase in skin blood flow and
50–60% increases in insulin absorption over a
4-h period in peoplewith diabetes [32]. At normal
ambient room temperature (22–24 C), a wide
range of local skin temperatures occur (30–37 C),
with a positive correlation observed between
serum insulin 45 min after injection and
temperature [33].
InsuPatch and InsuPad (InsuLine Medical,
Israel) are devices that employ the concept of
elevating the local skin temperature at the time
of subcutaneous prandial insulin injection to
modify insulin PK/PD. InsuPatch (Fig. 1) is
designed for insulin pump users. It consists of
a heating pad attached to the insulin pump
infusion set and a unit that controls and
monitors the temperature of the heating pad.
The heating pad is a flat circular patch with a
2-cm inner diameter and a 5-cm outer diameter
that incorporates battery-powered heating coils.
Following the delivery of an insulin bolus,
InsuPatch warms the tissue surrounding the
infusion set to 38.5 C for 30 min.
InsuPad (Fig. 2) consists of two units: a
warming electronic pad and a disposable
plastic frame. One part of the plastic frame
houses the warming unit whilst the other part
of the frame attaches to the skin with adhesive
tape to provide a window (42 9 60 mm)
through which prandial insulin doses can be
injected over 24 h. Following insulin
administration, closure of the plastic frame
exposes the injection site to the warming unit,
which is automatically activated. The unit
works for 50 min to apply three 10-min
warming intervals that increase the local skin
temperature to 40 C. There is a 10-min break
following each warming interval. At the end of
the day, removal of the warming unit destroys
the disposable frame and the unit is charged.
Fig. 1 Diagram of the InsuPatch device showing the
heating pad attached to the insulin pump’s infusion set
Fig. 2 Digital image of InsuPad showing the warming unit
and the disposable plastic frame
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InsuPad is CE marked and is currently approved
for marketing in a few countries, including
Israel, Canada and Germany. However, it is not
FDA approved yet.
Studies Evaluating the Effects of Local
Warming Devices
Evaluation of InsuPatch
The effects of InsuPatch on the PK and PD of
insulin were evaluated in 17 adults with type 1
diabetes (using insulin lispro or aspart). In this
open-label randomised crossover study, subjects
were randomised to InsuPatch or control (using
an infusion set without InsuPatch) arms before
crossover and underwent a meal tolerance test
glucose clamp. This 4-h study demonstrated
that the use of InsuPatch resulted in significant
acceleration of insulin absorption with earlier
onset of insulin exposure (early t50%max
decreased by 30%), acceleration of time to
insulin peak (tmax decreased by 43%), a
significant increase in maximum insulin
concentration (Cmax increased by 37%) and
significant increases in the AUC for insulin at
0–30, 0–60 and 0–90 min. The effect of the
device on the glucose profile showed significant
reductions in PPG excursions at 60 and 90 min
by 36% and 39%, respectively (Table 1).
Although the study demonstrated the
potential advantages of improving insulin PK/
PD using InsuPatch, it is limited by its small
data set: data on PK were obtained from only 9
of the 17 subjects [34].
Aiming to evaluate the effects of InsuPatch
on the PK and PD of insulin in a real-life setting
where subjects received continental breakfast
and dinner, a 4-day study was conducted in 24
adults with type 1 diabetes. The study
demonstrated that the use of InsuPatch
resulted in reductions in PPG of 14% and 40%
after breakfast and dinner, respectively [35].
In a larger study, a euglycaemic glucose
clamp technique was used to evaluate the
effects of InsuPatch. In this randomised
crossover study, 56 subjects with type 1
diabetes were randomised to either an
intervention phase or a control phase before
crossover. Compared to the control, the use of
InsuPatch resulted in a 30% increase in the AUC
of serum insulin in the first 60 min following
insulin bolus and a greater insulin peak
concentration (Cmax 57 vs 47.6 mU/L). Despite
the enhanced PK, this did not translate into
significant PD benefits [36].
The effect of InsuPatch was evaluated in two
studies in adolescents with type 1 diabetes. In
the first study, a euglycaemic glucose clamp
technique was used to evaluate the PK/PD of
insulin aspart with the use of the InsuPatch
device in 13 adolescents. Subjects underwent
two euglycaemic clamp procedures on separate
occasions: one with and one without InsuPatch
activation, in random order. During studies
where the InsuPatch was active, the infusion
site was warmed to 38.5 C 15 min prior to
bolus administration and remained warmed for
60–90 min after bolus administration. PK data
showed that the use of InsuPatch resulted in a
30% increase in maximal insulin increment
(DCmax 106 vs 81 uU/mL) and a shorter time to
reach this maximum increment (tmax 41 vs
67 min). It also resulted in 35% and 28%
increases in AUC for insulin increment over
the first 90 min and over the full 5 h,
respectively. This translated into enhanced PD
with a 28% acceleration of the peak of insulin
action (mean GIR tmax 90 vs 125 min) and a
36% increase in the overall glucose-lowering
effect for the first 90 min (GIR AUC0–90) [37].
The second study, which recruited 17
adolescents with type 1 diabetes, aimed to
evaluate the effect of InsuPatch at a higher
temperature (40 C). This resulted in a similar
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PD effect on GIR tmax and an 85% increase in
the overall glucose-lowering effect for the first
30 min (GIR AUC0–30) with InsuPatch
activation. This study also demonstrated that
the use of InsuPatch resulted in an acceleration
of the disappearance of the insulin bolus. The
time for the insulin level to return to baseline
was reduced from 200 to 183 min with
InsuPatch use. This implies a potential benefit
of InsuPatch use in reducing the risk of late
postprandial hypoglycaemia, resulting from the
effect of insulin stacking. The device was well
tolerated by all subjects despite the use of the
higher temperature [38]. It was not clear
whether the two most important unique
observations in this study (85% increase in
GIR AUC0–30 and the faster-out effect) were
related to the higher temperature (40 C), as
neither of those two variables were reported in
the earlier study [37]. Other PK/PD variables
were similar for the two studies. It is also
important to note that, in these two studies,
InsuPatch was activated 15 min before insulin
bolus and remained active for 60 min
afterwards. Despite the value of earlier
administration of RAIAs before mealtime, it is
difficult to consistently undertake this task, and
the pre-activation of the InsuPatch device
before mealtime could be similarly
challenging. These two studies are limited by
the small populations involved and the
inability to extrapolate the results beyond the
study populations.
A study of the effect of the InsuPatch on
automated closed-loop glucose control in type 1
diabetes is currently underway [39].
Evaluation of InsuPad
The InsuPad device was evaluated in a number
of meal tolerance studies that demonstrated the
potential benefits of InsuPad in lowering PPG
excursions in subjects with type 2 diabetes [40].
In an open-label randomised crossover meal
tolerance study, the effect of InsuPad on PPG
excursions was evaluated in subjects with type 2
diabetes treated with basal-bolus insulin
therapy. Glucose profiles demonstrated a 40%
reduction in the AUC of the PPG excursion
during the first 2 h following the meal when
InsuPad was used (Fig. 3). Insulin PK (Fig. 4)
showed that the use of InsuPad resulted in an
Fig. 3 Effect of InsuPad on postprandial glucose (black
circles) compared to the control (white squares) following a
liquid mixed meal in subjects with type 2 diabetes.
Figure reproduced with permission from SAGE publica-
tions Inc. [41]
Fig. 4 Effect of InsuPad use on insulin pharmacokinetics
(black circles) compared to the control (white squares)
following a liquid mixed meal in subjects with type 2
diabetes. Figure reproduced with permission from SAGE
publications Inc. [41]
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earlier insulin peak (tmax 52 vs 80 min), a shorter
duration (151 vs 190 min) and a significantly
higher AUC of insulin concentration in the first
hour after the meal (Table 2). The study also
demonstrated the effect of InsuPad in reducing
intersubject variability in relation to the time to
insulin peak. The use of InsuPad did not result
in skin irritation or inflammation in any of the
subjects [41].
Further evaluation of the device was
conducted in another study under more
real-life conditions. An open-label randomised
crossover study was conducted in 20 subjects
(14 with type 2 diabetes and 6 with type 1
diabetes) with insulin resistance (mean total
daily insulin dose of 0.97 U/kg body weight).
Subjects were randomised to either 4 weeks of
InsuPad use with breakfast and dinner or to
standard care before crossing over to the other
phase for 4 weeks. Capillary blood glucose was
monitored at least five times daily and insulin
doses were documented. PPG excursions
between 75 and 135 min after the meal were
analysed. Despite a significant reduction in PPG
excursions with InsuPad use, there was no
statistically significant difference in overall
mean glucose or biochemical hypo- and
hyperglycaemia. The study is limited by the
method of assessing PPG excursions. Valid pairs
of pre- and postprandial blood glucose
measurements were available for only 50% of
breakfasts and dinners [42].
The device was also evaluated in a larger
study under real conditions of daily life over a
period of 3 months. The Barmer study was
performed with 145 subjects (13 with type 1
diabetes and 132 with type 2 diabetes, aged
61.1 ± 8.4 years, BMI 35.5 ± 6.1 kg/m2). All
patients were on a basal bolus regimen using
RAIAs. Subjects underwent a 4-week run-in
period before randomisation to InsuPad
(intervention, n = 73) or not (control, n = 72).
Results showed an initial improvement in
HbA1c during the 4-week optimisation phase
in the whole study cohort [drop from 7.2 to
6.8% (P\0.001)]. At the end of the 3-month
study, the two groups showed similar
improvements in glycaemic control, with a
further significant drop of HbA1c to 6.3%
observed in the two groups. However, the
prandial insulin requirement in the
intervention group was 19% lower than
baseline (drop from 70 to 55 U). In
comparison, subjects in the control group
needed an 8.1% increase in their prandial
insulin requirements. There was an increase of
3.4% in basal insulin requirements in the
intervention group. The total daily dose of
insulin was increased by 3.7% in the control
group, while it was reduced by 8.6% in the
intervention group (P\0.001). The study also
evaluated the number of hypoglycaemic events
(CBG\3.5 mmol/L) in each group. This was
46% lower in the intervention group (3.3 vs 6.2
episodes/patient). However, there was no
statistically significant difference in the
number of severe hypoglycaemic events. There
was also no statistically significant difference in
change in body weight or number of
hyperglycaemic events. While the study
demonstrates the potential clinical value of
InsuPad, it is limited by its open-label design,
mixed diabetes cohort, and by the inability to
extrapolate the result beyond the study
population [43].
One of the acknowledged limitations of the
Barmer study was the reliability of self-reported
prandial insulin dose information. Aiming to
confirm the findings of the Barmer study and to
demonstrate the noninferiority of the reduced
prandial insulin dose observed in the
intervention group, a substudy of the original
Barmer study involving all subjects from one
study site was performed. Thirty-two subjects
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underwent a 5-h meal tolerance test with a
standardised insulin dose at baseline and at the
end of 3 months of randomisation to InsuPad
use or control. Baseline and 3-month data were
similar to those in the original Barmer study.
Despite reduction of prandial insulin dose by
almost 20% in the InsuPad group at 3 months,
insulin PK showed enhanced insulin
absorption, with a 40% reduction in the time
to reach maximal insulin concentration (tmax
reduced from 99 min at baseline to 60 min at
3 months). In comparison, tmax in the control
group remained around 70 min. Cmax and PPG
at 3 months were similar in the two groups [44].
To evaluate the effect of delayed prandial
insulin administration with the use of the
InsuPad device on the postprandial glucose
profile, a 5-h meal tolerance study was
conducted in 15 subjects with type 2 diabetes.
Subjects consumed standardised liquid meals
and the study was conducted twice: with the
InsuPad device (0.2 U/kg injected 30 min post
meal) and without the InsuPad device (0.2 U/kg
injected before meal). The use of InsuPad with
delayed prandial insulin administration showed
an earlier rise in glucose level. However, it
resulted in a lower mean maximum glucose
excursion (129 vs 142 mg/dL) and lower AUC
for postprandial glucose excursion over the 5-h
study (54 vs 70 mg/dL) [45, 46].
One of the secondary objectives of the
Barmer study was to evaluate the psychosocial
effect of the InsuPad. This was assessed using
the Diabetes Treatment Satisfaction
Questionnaire (DTSQ) and the Problem Areas
in Diabetes (PAID) questionnaire at the end of
the 3-month study. Despite the technical
demands associated with the use of the
InsuPad, the overall diabetes treatment
satisfaction was comparable between the
intervention and control groups. Similarly,
diabetes-related distress was comparable in theT
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two groups. In keeping with the reduction in
the frequency of nonsevere hypoglycaemia in
the intervention group, subjects in this group
reported lower unacceptably low blood glucose
levels (1.4 vs 1.9 in the control group; P\0.05).
Furthermore, 34.4% of the subjects in the
intervention group reported reduced pain
intensity in relation to insulin injections. This
should be compared to only 4.2% who reported
increased pain intensity with the use of the
InsuPad. More than 95% of the subjects in the
intervention group accepted an offer to
continue InsuPad use after the end of the
study [47].
A long-term follow-up open-label extension
of the Barmer study was performed in 52
patients who could be contacted after a
minimum of 13 months (mean usage time:
17.8 months, range: 13–21 months). In those
subjects, the initial benefits observed with
InsuPad use were maintained over 18 months.
HbA1c was stable at 6.4%, as was body weight.
However, the total daily insulin dose was
further reduced compared to baseline. Only 2
people stopped using the device because of a
persistent skin reaction to the adhesive [48].
CONCLUSION
Local warming devices (InsuPatch and InsuPad)
represent a simple method of enhancing the PK/
PD of subcutaneously injected insulin. Existing
evidence demonstrates the potential benefits of
using these devices in reducing PPG excursions,
improving metabolic control, reducing doses of
prandial insulin and decreasing nonsevere
hypoglycaemic events in obese
insulin-resistant subjects with well-controlled
diabetes. Moreover, the evidence suggests that
these devices are well tolerated and accepted by
users. Warming devices also provide the
potential to be combined with other methods
that enhance insulin absorption to further
augment their effect. However, existing studies
are small and heterogeneously designed and
some of them include heterogeneous
participants. Before these devices are approved
by different regulatory bodies and widely
adopted by clinicians and patients, more
appropriately designed large-scale longitudinal
studies are needed to demonstrate the effects of
these devices on clinical and patient-reported
outcomes in other subjects with different types
of diabetes and different baseline
characteristics, and to assess the health
economics of these devices.
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